Gene Tx For Hearing Loss With Sensorion's Nawal Ouzren
![23_01_BPO_BusBiotech_1200x628_Ep145 23_01_BPO_BusBiotech_1200x628_Ep145](https://vertassets.blob.core.windows.net/image/f72711bb/f72711bb-85c6-475c-9bf5-015264f0e033/375_250-23_01_bpo_busbiotech_1200x628_ep145.png)
We often talk about biotechs taking "big swings." This week's guest is swinging for the fences with a lineup of gene therapies designed to address multiple forms of hearing loss, which affect multiple millions (if not, billions) of people worldwide. Adding to the challenge she's accepted, Sensorion CEO Nawal Ouzren is architecting an approach that seeks to restore hearing that's been lost due to genetic factors, treat sudden hearing disorders, and proactively prevent hearing loss due to common causes such as cisplatin induced ototoxicity or cochlear implantation. Listen in as Ouzren shares her holistic and aggressive plans with the Business of Biotech.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.